DK3519416T3 - Chroman, isochroman og dihydroisobenzofuranderivater som mglur2-negative allosteriske modulatorer, sammensætninger og anvendelse deraf - Google Patents
Chroman, isochroman og dihydroisobenzofuranderivater som mglur2-negative allosteriske modulatorer, sammensætninger og anvendelse deraf Download PDFInfo
- Publication number
- DK3519416T3 DK3519416T3 DK17781253.4T DK17781253T DK3519416T3 DK 3519416 T3 DK3519416 T3 DK 3519416T3 DK 17781253 T DK17781253 T DK 17781253T DK 3519416 T3 DK3519416 T3 DK 3519416T3
- Authority
- DK
- Denmark
- Prior art keywords
- mglur2
- isochroman
- chroman
- compositions
- allosteric modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400150P | 2016-09-27 | 2016-09-27 | |
| PCT/US2017/053155 WO2018063955A1 (en) | 2016-09-27 | 2017-09-25 | CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3519416T3 true DK3519416T3 (da) | 2021-05-25 |
Family
ID=60043302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17781253.4T DK3519416T3 (da) | 2016-09-27 | 2017-09-25 | Chroman, isochroman og dihydroisobenzofuranderivater som mglur2-negative allosteriske modulatorer, sammensætninger og anvendelse deraf |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US10335399B2 (da) |
| EP (1) | EP3519416B1 (da) |
| JP (3) | JP6681517B2 (da) |
| KR (1) | KR102296043B1 (da) |
| CN (1) | CN109983022B (da) |
| AR (1) | AR109714A1 (da) |
| AU (2) | AU2017334870C1 (da) |
| CA (1) | CA3037537C (da) |
| CL (1) | CL2019000778A1 (da) |
| CO (1) | CO2019002673A2 (da) |
| CR (1) | CR20190147A (da) |
| CY (1) | CY1124346T1 (da) |
| DK (1) | DK3519416T3 (da) |
| DO (1) | DOP2019000076A (da) |
| EA (1) | EA038627B1 (da) |
| EC (1) | ECSP19020742A (da) |
| ES (1) | ES2868973T3 (da) |
| GE (2) | GEP20217279B (da) |
| HR (1) | HRP20210793T1 (da) |
| HU (1) | HUE054898T2 (da) |
| IL (1) | IL265366B (da) |
| JO (1) | JOP20190058B1 (da) |
| LT (1) | LT3519416T (da) |
| MA (1) | MA46342B1 (da) |
| MD (1) | MD3519416T2 (da) |
| MX (1) | MX2019003492A (da) |
| MY (1) | MY196807A (da) |
| NI (1) | NI201900025A (da) |
| PE (1) | PE20190609A1 (da) |
| PH (1) | PH12019500597A1 (da) |
| PL (1) | PL3519416T3 (da) |
| PT (1) | PT3519416T (da) |
| RS (1) | RS61890B1 (da) |
| SI (1) | SI3519416T1 (da) |
| TN (2) | TN2020000161A1 (da) |
| TW (1) | TWI764934B (da) |
| UA (1) | UA123687C2 (da) |
| WO (1) | WO2018063955A1 (da) |
| ZA (1) | ZA201901701B (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6681517B2 (ja) * | 2016-09-27 | 2020-04-15 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ｍＧｌｕＲ２陰性アロステリック調節剤としてのクロマン、イソクロマン及びジヒドロイソベンゾフラン誘導体、組成物、及びそれらの使用 |
| UY38057A (es) | 2018-01-19 | 2019-08-30 | Cytokinetics Inc | Inhibidores de sarcómero cardíaco |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| UA127368C2 (uk) * | 2019-03-01 | 2023-07-26 | Кбп Байосайєнсіз Ко., Лтд. | Спосіб одержання трициклічної сполуки і її проміжного продукту |
| US11919909B2 (en) | 2021-03-04 | 2024-03-05 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| WO2023278729A1 (en) * | 2021-06-30 | 2023-01-05 | The General Hospital Corporation | Chromane imaging ligands |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552437A (en) | 1994-10-27 | 1996-09-03 | Merck Frosst Canada, Inc. | Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis |
| US5576338A (en) | 1995-02-15 | 1996-11-19 | Merck Frosst Canada, Inc. | Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis |
| WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用 |
| EP1934205A4 (en) | 2005-10-05 | 2010-06-02 | Merck Frosst Canada Ltd | SUBSTITUTED QUINOLINES AS INHIBITORS OF LEUCOTRIENE BIOSYNTHESIS |
| AR065093A1 (es) | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| US20120040974A1 (en) | 2008-08-18 | 2012-02-16 | Yale University | Mif modulators |
| MX2011011964A (es) * | 2009-05-12 | 2012-02-23 | Janssen Pharmaceuticals Inc | Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos. |
| WO2011075699A2 (en) | 2009-12-18 | 2011-06-23 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| KR20140088887A (ko) * | 2011-11-03 | 2014-07-11 | 머크 샤프 앤드 돔 코포레이션 | mGluR2-음성 알로스테릭 조절제로서의 퀴놀린 카르복스아미드 및 퀴놀린 카르보니트릴 유도체, 조성물, 및 그의 용도 |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| WO2016029454A1 (en) | 2014-08-29 | 2016-03-03 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
| US9382208B1 (en) | 2015-01-26 | 2016-07-05 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 2 |
| WO2016149324A1 (en) | 2015-03-16 | 2016-09-22 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 2 |
| JP6471614B2 (ja) | 2015-05-29 | 2019-02-20 | 株式会社リコー | 通信端末、通信システム、通信制御方法、及びプログラム |
| JP2018154554A (ja) | 2015-07-29 | 2018-10-04 | 大日本住友製薬株式会社 | 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途 |
| JP6681517B2 (ja) | 2016-09-27 | 2020-04-15 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ｍＧｌｕＲ２陰性アロステリック調節剤としてのクロマン、イソクロマン及びジヒドロイソベンゾフラン誘導体、組成物、及びそれらの使用 |
-
2017
- 2017-09-25 JP JP2019516203A patent/JP6681517B2/ja active Active
- 2017-09-25 MY MYPI2019001659A patent/MY196807A/en unknown
- 2017-09-25 GE GEAP201715310A patent/GEP20217279B/en unknown
- 2017-09-25 CN CN201780071759.0A patent/CN109983022B/zh active Active
- 2017-09-25 CR CR20190147A patent/CR20190147A/es unknown
- 2017-09-25 TN TNP/2020/000161A patent/TN2020000161A1/en unknown
- 2017-09-25 PT PT177812534T patent/PT3519416T/pt unknown
- 2017-09-25 SI SI201730727T patent/SI3519416T1/sl unknown
- 2017-09-25 TN TNP/2020/000160A patent/TN2020000160A1/en unknown
- 2017-09-25 HU HUE17781253A patent/HUE054898T2/hu unknown
- 2017-09-25 US US15/713,769 patent/US10335399B2/en active Active
- 2017-09-25 ES ES17781253T patent/ES2868973T3/es active Active
- 2017-09-25 AU AU2017334870A patent/AU2017334870C1/en active Active
- 2017-09-25 AR ARP170102642A patent/AR109714A1/es unknown
- 2017-09-25 UA UAA201904545A patent/UA123687C2/uk unknown
- 2017-09-25 KR KR1020197011789A patent/KR102296043B1/ko active IP Right Grant
- 2017-09-25 MD MDE20190867T patent/MD3519416T2/ro unknown
- 2017-09-25 PE PE2019000706A patent/PE20190609A1/es unknown
- 2017-09-25 WO PCT/US2017/053155 patent/WO2018063955A1/en unknown
- 2017-09-25 DK DK17781253.4T patent/DK3519416T3/da active
- 2017-09-25 JO JOP/2019/0058A patent/JOP20190058B1/ar active
- 2017-09-25 RS RS20210649A patent/RS61890B1/sr unknown
- 2017-09-25 MX MX2019003492A patent/MX2019003492A/es unknown
- 2017-09-25 EP EP17781253.4A patent/EP3519416B1/en active Active
- 2017-09-25 TW TW106132824A patent/TWI764934B/zh active
- 2017-09-25 MA MA46342A patent/MA46342B1/fr unknown
- 2017-09-25 EA EA201990818A patent/EA038627B1/ru unknown
- 2017-09-25 CA CA3037537A patent/CA3037537C/en active Active
- 2017-09-25 GE GEAP201715056A patent/GEP20217266B/en unknown
- 2017-09-25 PL PL17781253T patent/PL3519416T3/pl unknown
- 2017-09-25 LT LTEP17781253.4T patent/LT3519416T/lt unknown
-
2019
- 2019-03-13 IL IL265366A patent/IL265366B/en unknown
- 2019-03-19 ZA ZA2019/01701A patent/ZA201901701B/en unknown
- 2019-03-19 PH PH12019500597A patent/PH12019500597A1/en unknown
- 2019-03-20 NI NI201900025A patent/NI201900025A/es unknown
- 2019-03-22 CO CONC2019/0002673A patent/CO2019002673A2/es unknown
- 2019-03-25 CL CL2019000778A patent/CL2019000778A1/es unknown
- 2019-03-26 DO DO2019000076A patent/DOP2019000076A/es unknown
- 2019-03-28 EC ECSENADI201920742A patent/ECSP19020742A/es unknown
- 2019-04-23 US US16/392,131 patent/US10806724B2/en active Active
- 2019-09-30 JP JP2019178232A patent/JP6945605B2/ja active Active
-
2020
- 2020-03-23 JP JP2020051049A patent/JP6992109B2/ja active Active
- 2020-09-25 US US17/032,626 patent/US20210015800A1/en not_active Abandoned
- 2020-11-16 AU AU2020270468A patent/AU2020270468B2/en active Active
-
2021
- 2021-05-17 HR HRP20210793TT patent/HRP20210793T1/hr unknown
- 2021-05-31 CY CY20211100468T patent/CY1124346T1/el unknown
-
2022
- 2022-03-15 US US17/695,262 patent/US20220218676A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3519416T3 (da) | Chroman, isochroman og dihydroisobenzofuranderivater som mglur2-negative allosteriske modulatorer, sammensætninger og anvendelse deraf | |
| DK3394033T3 (da) | Heterocykliske forbindelser som immunmodulatorer | |
| DK3407888T3 (da) | Pyridopyrroloquinoxalinforbindelser, deres sammensætninger og anvendelser | |
| DK3347472T3 (da) | Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf. | |
| EP3229789A4 (en) | Microencapsulated cannabinoid compositions | |
| DK3328849T5 (da) | 1,1,1-trifluor-3-hydroxypropan-2-yl-carbamat-derivater og 1,1,1-trifluor-4-hydroxybutan-2-yl-carbamat-derivater som magl-inhibitorer | |
| DK3258942T3 (da) | Kosmetiske og topiske sammensætninger omfattende cannabigerol og cannabidiol | |
| IL243671A0 (en) | Sulfonamides for modulating sodium channels, preparations containing them and their uses | |
| DK3363790T3 (da) | 1,2,4-oxadiazolderivater som immunmodulatorer | |
| EP3283080A4 (en) | Compositions for modulating c9orf72 expression | |
| DK3294713T3 (da) | Substituerede tetrahydroquinolinonforbindelser som ror-gamma-modulatorer | |
| DK3313832T3 (da) | 3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere | |
| DK3071709T3 (da) | Mikrobiotasammensætning som en markør for modtagelighed over for kemoterapi og anvendelse af mikrobielle modulatorer (præ-, pro- eller synbiotika) til forbedring af virkningsgraden af en cancerbehandling | |
| DK3377483T3 (da) | N-substituerede indolderivater som pge2-receptormodulatorer | |
| DK3331863T3 (da) | Hidtil ukendte forbindelser som ror-gamma-modulatorer | |
| DK3625222T3 (da) | Phenylderivater som pge2-receptormodulatorer | |
| DK2861573T3 (da) | Oxathiazin-derivater som antibakterielle og anticancer-stoffer | |
| DK3126361T3 (da) | Chromen og 1,1a,2,7b-tetrahydrocyclopropa[c]chromen- pyridopyrazindioner som gamma-sekretase-modulatorer | |
| DK3292105T3 (da) | Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap) | |
| DK3464260T3 (da) | Forbindelser, der indeholder ureamotiver, og derivater deraf som antibakterielle lægemidler | |
| EP3185865A4 (en) | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE | |
| DK3003493T3 (da) | Enzymatisk system, som indeholder kosmetiske sammensætninger | |
| DK3468964T3 (da) | Modulatorer af SOCE, sammensætninger og anvendelser deraf | |
| DK3145916T3 (da) | Imidazolderivater som formylpeptidreceptormodulatorer | |
| DK3383397T3 (da) | Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin |